Literature DB >> 24933439

Eph receptor tyrosine kinases in cancer stem cells.

Jin Chen1, Wenqiang Song2, Katherine Amato3.   

Abstract

Eph receptor tyrosine kinases (RTKs) and their ligands, ephrins, play critical roles in development, tissue homeostasis, and cancer. Because Eph receptors are expressed in most adult stem cell niches and in many types of cancers, it has been long suspected that this family of RTKs may also regulate the function of cancer stem-like cells (CSCs). This review will focus on recent studies to elucidate the contribution of Eph/ephrin molecules in CSC self-renewal and tumorigenicity, as well as describe efforts to target these molecules in cancer. Because CSCs are often resistant to therapeutic intervention and have been shown to depend on Eph RTKs for self-renewal, targeting Eph receptors may hold promise for the treatment of drug-resistant cancers. Published by Elsevier Ltd.

Entities:  

Keywords:  Cancer stem cells; Eph RTK; Ephrin

Mesh:

Substances:

Year:  2014        PMID: 24933439      PMCID: PMC4234705          DOI: 10.1016/j.cytogfr.2014.05.001

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  65 in total

1.  EphB receptors regulate stem/progenitor cell proliferation, migration, and polarity during hippocampal neurogenesis.

Authors:  Michael J Chumley; Timothy Catchpole; Robert E Silvany; Steven G Kernie; Mark Henkemeyer
Journal:  J Neurosci       Date:  2007-12-05       Impact factor: 6.167

Review 2.  Targeting cancer with small molecule kinase inhibitors.

Authors:  Jianming Zhang; Priscilla L Yang; Nathanael S Gray
Journal:  Nat Rev Cancer       Date:  2009-01       Impact factor: 60.716

3.  Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors.

Authors:  Roberta Noberini; Mitchell Koolpe; Satyamaheshwar Peddibhotla; Russell Dahl; Ying Su; Nicholas D P Cosford; Gregory P Roth; Elena B Pasquale
Journal:  J Biol Chem       Date:  2008-08-26       Impact factor: 5.157

Review 4.  Eph-ephrin bidirectional signaling in physiology and disease.

Authors:  Elena B Pasquale
Journal:  Cell       Date:  2008-04-04       Impact factor: 41.582

5.  A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases.

Authors:  Huaibin Chen; Jinghong Ma; Wanqing Li; Anna V Eliseenkova; Chongfeng Xu; Thomas A Neubert; W Todd Miller; Moosa Mohammadi
Journal:  Mol Cell       Date:  2007-09-07       Impact factor: 17.970

6.  Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility.

Authors:  Alice Bjerregaard Larsen; Mikkel Wandahl Pedersen; Marie-Thérése Stockhausen; Michael Vibo Grandal; Bo van Deurs; Hans Skovgaard Poulsen
Journal:  Mol Cancer Res       Date:  2007-03       Impact factor: 5.852

Review 7.  Clinical relevance of Ephs and ephrins in cancer: lessons from breast, colorectal, and lung cancer profiling.

Authors:  Dana M Brantley-Sieders
Journal:  Semin Cell Dev Biol       Date:  2011-10-21       Impact factor: 7.727

8.  The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling.

Authors:  Dana M Brantley-Sieders; Guanglei Zhuang; Donna Hicks; Wei Bin Fang; Yoonha Hwang; Justin M M Cates; Karen Coffman; Dowdy Jackson; Elizabeth Bruckheimer; Rebecca S Muraoka-Cook; Jin Chen
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

9.  Identification of stem cells in small intestine and colon by marker gene Lgr5.

Authors:  Nick Barker; Johan H van Es; Jeroen Kuipers; Pekka Kujala; Maaike van den Born; Miranda Cozijnsen; Andrea Haegebarth; Jeroen Korving; Harry Begthel; Peter J Peters; Hans Clevers
Journal:  Nature       Date:  2007-10-14       Impact factor: 49.962

10.  Expression of Eph receptors and ephrins is differentially regulated by E-cadherin.

Authors:  S Orsulic; R Kemler
Journal:  J Cell Sci       Date:  2000-05       Impact factor: 5.285

View more
  15 in total

1.  Novel Roles and Mechanism for Krüppel-like Factor 16 (KLF16) Regulation of Neurite Outgrowth and Ephrin Receptor A5 (EphA5) Expression in Retinal Ganglion Cells.

Authors:  Jianbo Wang; Joana Galvao; Krista M Beach; Weijia Luo; Raul A Urrutia; Jeffrey L Goldberg; Deborah C Otteson
Journal:  J Biol Chem       Date:  2016-07-11       Impact factor: 5.157

2.  Structural Analysis of the Binding of Type I, I1/2, and II Inhibitors to Eph Tyrosine Kinases.

Authors:  Jing Dong; Hongtao Zhao; Ting Zhou; Dimitrios Spiliotopoulos; Chitra Rajendran; Xiao-Dan Li; Danzhi Huang; Amedeo Caflisch
Journal:  ACS Med Chem Lett       Date:  2014-09-29       Impact factor: 4.345

Review 3.  Eph Receptor Tyrosine Kinases in Tumor Immunity.

Authors:  Eileen Shiuan; Jin Chen
Journal:  Cancer Res       Date:  2016-11-03       Impact factor: 12.701

Review 4.  Ephs and Ephrins in malignant gliomas.

Authors:  Sara Ferluga; Waldemar Debinski
Journal:  Growth Factors       Date:  2014-11-24       Impact factor: 2.511

5.  Cancer stem cells as a potential therapeutic target in thyroid carcinoma.

Authors:  Luisa Vicari; Cristina Colarossi; Dario Giuffrida; Ruggero De Maria; Lorenzo Memeo
Journal:  Oncol Lett       Date:  2016-08-02       Impact factor: 2.967

6.  Characterizing the Hot Spots Involved in RON-MSPβ Complex Formation Using In Silico Alanine Scanning Mutagenesis and Molecular Dynamics Simulation.

Authors:  Omid Zarei; Maryam Hamzeh-Mivehroud; Silvia Benvenuti; Fulya Ustun-Alkan; Siavoush Dastmalchi
Journal:  Adv Pharm Bull       Date:  2017-04-13

7.  Identifying and Analyzing Novel Epilepsy-Related Genes Using Random Walk with Restart Algorithm.

Authors:  Wei Guo; Dong-Mei Shang; Jing-Hui Cao; Kaiyan Feng; Yi-Chun He; Yang Jiang; ShaoPeng Wang; Yu-Fei Gao
Journal:  Biomed Res Int       Date:  2017-02-01       Impact factor: 3.411

8.  UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice.

Authors:  Claudio Festuccia; Giovanni Luca Gravina; Carmine Giorgio; Andrea Mancini; Cristina Pellegrini; Alessandro Colapietro; Simona Delle Monache; Maria Giovanna Maturo; Roberta Sferra; Paola Chiodelli; Marco Rusnati; Annamaria Cantoni; Riccardo Castelli; Federica Vacondio; Alessio Lodola; Massimiliano Tognolini
Journal:  Oncotarget       Date:  2018-05-11

9.  EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours.

Authors:  Behzad M Toosi; Amr El Zawily; Luke Truitt; Matthew Shannon; Odette Allonby; Mohan Babu; John DeCoteau; Darrell Mousseau; Mohsin Ali; Tanya Freywald; Amanda Gall; Frederick S Vizeacoumar; Morgan W Kirzinger; C Ronald Geyer; Deborah H Anderson; TaeHyung Kim; Alana L Welm; Peter Siegel; Franco J Vizeacoumar; Anthony Kusalik; Andrew Freywald
Journal:  Oncogene       Date:  2018-04-27       Impact factor: 9.867

10.  Anks1a regulates COPII-mediated anterograde transport of receptor tyrosine kinases critical for tumorigenesis.

Authors:  Haeryung Lee; Hyuna Noh; Jiyoung Mun; Changkyu Gu; Sanja Sever; Soochul Park
Journal:  Nat Commun       Date:  2016-09-13       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.